Now FDA Approved
For adults with relapsed or refractory
multiple myeloma
ELREXFIO treats adults with multiple myeloma who have already received at least four treatment regimens and their cancer has come back or did not respond to prior treatment.
ELREXFIO is approved based on patient response. Data are not yet available to show if ELREXFIO improves survival or symptoms.
Sign up to stay informed about important updates for ELREXFIO.
Getting started with ELREXFIO
Download this helpful guide when beginning your treatment. It may help answer some of your frequently asked questions about ELREXFIO.
Learn about the FDA approval
Find out about the FDA approval of ELREXFIO and this important development in multiple myeloma treatment.
Making your support needs a priority. Together.
Managing day-to-day life after diagnosis can be overwhelming, but you don’t have to do it alone. Pfizer Oncology Together is a support program that treats your individual needs as a priority.
Personalized support throughout treatment with ELREXFIO
If you’ve been prescribed ELREXFIO, you can receive one-on-one support from a Pfizer Patient Access Navigator during your treatment. Whether you have questions about getting started on treatment or need help understanding what your plan may look like, you can turn to your Patient Access Navigator for support.
Support & financial resources
If needed, we’ll help you find financial assistance options for your ELREXFIO treatment, including a co-pay savings program for eligible, commercially insured patients. Limits, terms, and conditions apply. If you need financial assistance, we can also help identify resources if you have Medicare, another government insurance plan, or don’t have health insurance.
Co-pay assistance
Eligible,* commercially insured patients† may pay as little as $0 per treatment for ELREXFIO, regardless of income.‡ Limits, terms, and conditions apply.